 Aaron Michels
Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 66 | 2025 | 3628 | 7.240 |
Why?
| | Autoantigens | 17 | 2025 | 419 | 3.440 |
Why?
| | Receptors, Antigen, T-Cell | 15 | 2024 | 704 | 3.380 |
Why?
| | Insulin | 28 | 2024 | 2325 | 3.080 |
Why?
| | Islets of Langerhans | 16 | 2024 | 789 | 2.760 |
Why?
| | Autoantibodies | 22 | 2025 | 1467 | 2.530 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2022 | 181 | 1.970 |
Why?
| | T-Lymphocytes | 12 | 2023 | 1933 | 1.950 |
Why?
| | Programmed Cell Death 1 Receptor | 4 | 2019 | 232 | 1.700 |
Why?
| | HLA Antigens | 4 | 2025 | 234 | 1.570 |
Why?
| | Insulin-Secreting Cells | 9 | 2022 | 364 | 1.550 |
Why?
| | CD4-Positive T-Lymphocytes | 15 | 2025 | 1056 | 1.540 |
Why?
| | Hypoglycemic Agents | 9 | 2020 | 1219 | 1.450 |
Why?
| | Autoimmunity | 14 | 2024 | 862 | 1.440 |
Why?
| | Antibodies, Monoclonal | 5 | 2020 | 1367 | 1.330 |
Why?
| | Autoimmune Diseases | 5 | 2019 | 426 | 1.170 |
Why?
| | Insulin Antibodies | 4 | 2017 | 105 | 1.160 |
Why?
| | Peptides | 6 | 2023 | 923 | 1.140 |
Why?
| | Histocompatibility Antigens Class II | 7 | 2018 | 363 | 1.060 |
Why?
| | HLA-DQ Antigens | 7 | 2019 | 179 | 1.030 |
Why?
| | Immunologic Factors | 3 | 2019 | 230 | 1.000 |
Why?
| | HLA-DR Antigens | 3 | 2022 | 223 | 0.950 |
Why?
| | Antigen Presentation | 2 | 2018 | 207 | 0.880 |
Why?
| | Melanoma | 2 | 2022 | 729 | 0.860 |
Why?
| | Protein Precursors | 3 | 2021 | 128 | 0.850 |
Why?
| | B7-H1 Antigen | 3 | 2021 | 195 | 0.800 |
Why?
| | Models, Immunological | 2 | 2015 | 95 | 0.780 |
Why?
| | Cell Cycle Checkpoints | 2 | 2020 | 95 | 0.780 |
Why?
| | Peptide Fragments | 6 | 2016 | 692 | 0.770 |
Why?
| | Immunotherapy | 7 | 2021 | 592 | 0.770 |
Why?
| | Humans | 77 | 2025 | 129271 | 0.770 |
Why?
| | Methyldopa | 2 | 2019 | 7 | 0.750 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 5 | 2025 | 63 | 0.680 |
Why?
| | HLA-DQ beta-Chains | 1 | 2020 | 61 | 0.670 |
Why?
| | Polyendocrinopathies, Autoimmune | 2 | 2010 | 18 | 0.650 |
Why?
| | Disease Susceptibility | 1 | 2021 | 333 | 0.650 |
Why?
| | Health Fairs | 1 | 2019 | 9 | 0.650 |
Why?
| | Interferon-gamma | 2 | 2021 | 772 | 0.650 |
Why?
| | Stevens-Johnson Syndrome | 2 | 2019 | 38 | 0.630 |
Why?
| | Antigens | 4 | 2018 | 356 | 0.630 |
Why?
| | Child | 29 | 2025 | 20785 | 0.580 |
Why?
| | Preventive Medicine | 1 | 2018 | 41 | 0.580 |
Why?
| | Proinsulin | 2 | 2017 | 52 | 0.560 |
Why?
| | Alleles | 5 | 2022 | 845 | 0.560 |
Why?
| | Diabetic Ketoacidosis | 4 | 2025 | 197 | 0.560 |
Why?
| | Epitopes | 5 | 2025 | 470 | 0.550 |
Why?
| | Antibody Formation | 1 | 2018 | 291 | 0.530 |
Why?
| | Adolescent | 26 | 2025 | 20315 | 0.520 |
Why?
| | Influenza, Human | 1 | 2022 | 601 | 0.520 |
Why?
| | Immunity, Cellular | 1 | 2018 | 265 | 0.510 |
Why?
| | Dried Blood Spot Testing | 1 | 2016 | 94 | 0.510 |
Why?
| | Genetic Predisposition to Disease | 8 | 2025 | 2276 | 0.500 |
Why?
| | Rituximab | 1 | 2016 | 164 | 0.470 |
Why?
| | Major Histocompatibility Complex | 2 | 2013 | 230 | 0.470 |
Why?
| | Graft Rejection | 1 | 2018 | 598 | 0.460 |
Why?
| | Hypoglycemia | 3 | 2016 | 427 | 0.460 |
Why?
| | HLA-D Antigens | 1 | 2014 | 34 | 0.460 |
Why?
| | Lymphocyte Activation | 4 | 2020 | 1109 | 0.450 |
Why?
| | Diet Therapy | 1 | 2014 | 34 | 0.450 |
Why?
| | Mice, Inbred NOD | 8 | 2024 | 588 | 0.450 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 890 | 0.450 |
Why?
| | Drug Hypersensitivity | 1 | 2015 | 81 | 0.450 |
Why?
| | Adrenal Glands | 1 | 2014 | 70 | 0.440 |
Why?
| | Addison Disease | 1 | 2014 | 43 | 0.440 |
Why?
| | Young Adult | 18 | 2025 | 12392 | 0.430 |
Why?
| | Antibodies | 1 | 2015 | 398 | 0.430 |
Why?
| | Mass Screening | 3 | 2019 | 1149 | 0.420 |
Why?
| | Hormone Replacement Therapy | 1 | 2014 | 92 | 0.410 |
Why?
| | Biomarkers | 3 | 2021 | 3968 | 0.410 |
Why?
| | Disease Progression | 6 | 2021 | 2630 | 0.400 |
Why?
| | Child, Preschool | 15 | 2025 | 10459 | 0.400 |
Why?
| | Blood Glucose | 4 | 2024 | 2097 | 0.390 |
Why?
| | Prediabetic State | 1 | 2015 | 244 | 0.390 |
Why?
| | Female | 37 | 2025 | 68556 | 0.380 |
Why?
| | Male | 34 | 2025 | 63517 | 0.380 |
Why?
| | Organophosphorus Compounds | 1 | 2011 | 78 | 0.350 |
Why?
| | Infant | 10 | 2025 | 8975 | 0.350 |
Why?
| | Glycine | 1 | 2011 | 165 | 0.350 |
Why?
| | Animals | 22 | 2024 | 35309 | 0.350 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 2010 | 8 | 0.340 |
Why?
| | Struma Ovarii | 1 | 2010 | 7 | 0.340 |
Why?
| | Macromolecular Substances | 1 | 2010 | 216 | 0.330 |
Why?
| | Endocrine System Diseases | 1 | 2010 | 33 | 0.330 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 854 | 0.320 |
Why?
| | Adult | 28 | 2025 | 35497 | 0.320 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 336 | 0.310 |
Why?
| | C-Peptide | 5 | 2016 | 163 | 0.310 |
Why?
| | Transcription Factor 7-Like 2 Protein | 2 | 2018 | 22 | 0.290 |
Why?
| | Haplotypes | 3 | 2020 | 475 | 0.290 |
Why?
| | Carbamazepine | 2 | 2019 | 19 | 0.290 |
Why?
| | Inflammation | 2 | 2017 | 2737 | 0.280 |
Why?
| | Neoplasms | 2 | 2020 | 2449 | 0.280 |
Why?
| | Pediatrics | 1 | 2015 | 1049 | 0.280 |
Why?
| | Glutamate Decarboxylase | 4 | 2017 | 166 | 0.270 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2020 | 2439 | 0.270 |
Why?
| | Middle Aged | 20 | 2022 | 31091 | 0.260 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2021 | 857 | 0.260 |
Why?
| | Antilymphocyte Serum | 2 | 2016 | 63 | 0.250 |
Why?
| | Granulocyte Colony-Stimulating Factor | 2 | 2016 | 72 | 0.250 |
Why?
| | History, 21st Century | 2 | 2018 | 183 | 0.240 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2024 | 601 | 0.240 |
Why?
| | History, 20th Century | 2 | 2018 | 291 | 0.230 |
Why?
| | Ovarian Neoplasms | 1 | 2010 | 489 | 0.230 |
Why?
| | Pluripotent Stem Cells | 2 | 2022 | 77 | 0.220 |
Why?
| | Mice | 12 | 2024 | 16915 | 0.220 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2024 | 126 | 0.220 |
Why?
| | Hybridomas | 3 | 2020 | 235 | 0.210 |
Why?
| | Age of Onset | 1 | 2025 | 496 | 0.210 |
Why?
| | Protein Binding | 3 | 2021 | 2120 | 0.210 |
Why?
| | Lipodystrophy, Congenital Generalized | 1 | 2023 | 1 | 0.210 |
Why?
| | Lipodystrophy | 1 | 2023 | 13 | 0.210 |
Why?
| | CD3 Complex | 2 | 2020 | 103 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 833 | 0.190 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2022 | 373 | 0.180 |
Why?
| | Histocompatibility Antigens | 1 | 2021 | 107 | 0.180 |
Why?
| | Insulin, Regular, Human | 1 | 2020 | 43 | 0.180 |
Why?
| | Molecular Sequence Data | 3 | 2015 | 2835 | 0.180 |
Why?
| | Polyethylene Glycols | 2 | 2016 | 587 | 0.180 |
Why?
| | Rhizotomy | 1 | 2000 | 4 | 0.170 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 1004 | 0.170 |
Why?
| | Virus Diseases | 2 | 2015 | 210 | 0.170 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2018 | 2063 | 0.170 |
Why?
| | Brachial Plexus | 1 | 2000 | 28 | 0.170 |
Why?
| | Glucagon-Like Peptides | 1 | 2020 | 50 | 0.170 |
Why?
| | Retroviridae | 1 | 2020 | 99 | 0.170 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2021 | 200 | 0.160 |
Why?
| | Case-Control Studies | 3 | 2022 | 3377 | 0.160 |
Why?
| | Muscle Spasticity | 1 | 2000 | 55 | 0.160 |
Why?
| | Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2019 | 9 | 0.160 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2019 | 14 | 0.160 |
Why?
| | Stem Cells | 2 | 2021 | 574 | 0.160 |
Why?
| | Arm | 1 | 2000 | 107 | 0.160 |
Why?
| | Immunoassay | 1 | 2020 | 107 | 0.160 |
Why?
| | Blood Specimen Collection | 1 | 2019 | 35 | 0.160 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 485 | 0.160 |
Why?
| | Genotype | 2 | 2015 | 1835 | 0.150 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2019 | 169 | 0.150 |
Why?
| | HLA-DRB1 Chains | 1 | 2019 | 108 | 0.150 |
Why?
| | Prognosis | 2 | 2018 | 3773 | 0.150 |
Why?
| | Models, Molecular | 2 | 2015 | 1487 | 0.150 |
Why?
| | Cell Line, Transformed | 1 | 2018 | 140 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2014 | 758 | 0.150 |
Why?
| | Transglutaminases | 2 | 2016 | 153 | 0.140 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 138 | 0.140 |
Why?
| | Community Health Services | 1 | 2019 | 226 | 0.140 |
Why?
| | Treatment Outcome | 5 | 2019 | 10202 | 0.140 |
Why?
| | Tissue Donors | 2 | 2021 | 391 | 0.140 |
Why?
| | Genetic Heterogeneity | 1 | 2017 | 58 | 0.140 |
Why?
| | Treatment Failure | 1 | 2018 | 339 | 0.140 |
Why?
| | Antibodies, Viral | 1 | 2021 | 601 | 0.130 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2016 | 27 | 0.130 |
Why?
| | Amino Acid Sequence | 3 | 2017 | 2056 | 0.130 |
Why?
| | Radioimmunoassay | 1 | 2016 | 175 | 0.130 |
Why?
| | Genetic Variation | 1 | 2021 | 938 | 0.130 |
Why?
| | Luminescence | 1 | 2016 | 36 | 0.130 |
Why?
| | Mutation | 3 | 2015 | 3710 | 0.130 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2117 | 0.130 |
Why?
| | Administration, Oral | 1 | 2018 | 785 | 0.130 |
Why?
| | Dideoxynucleosides | 1 | 2015 | 20 | 0.120 |
Why?
| | Luminescent Measurements | 1 | 2016 | 75 | 0.120 |
Why?
| | Donor Selection | 1 | 2016 | 75 | 0.120 |
Why?
| | Immunologic Memory | 1 | 2017 | 349 | 0.120 |
Why?
| | Antigen-Presenting Cells | 1 | 2015 | 151 | 0.120 |
Why?
| | Monocytes | 2 | 2016 | 551 | 0.120 |
Why?
| | Abatacept | 1 | 2014 | 46 | 0.110 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 372 | 0.110 |
Why?
| | Vitamin B Complex | 1 | 2014 | 41 | 0.110 |
Why?
| | Multifactorial Inheritance | 1 | 2015 | 150 | 0.110 |
Why?
| | Niacinamide | 1 | 2014 | 75 | 0.110 |
Why?
| | Early Medical Intervention | 1 | 2014 | 57 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2015 | 172 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2014 | 100 | 0.110 |
Why?
| | B-Lymphocytes | 1 | 2019 | 815 | 0.110 |
Why?
| | Chromogranin A | 1 | 2013 | 42 | 0.110 |
Why?
| | CD4 Antigens | 1 | 2013 | 138 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2014 | 218 | 0.100 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 45 | 0.100 |
Why?
| | Immunoconjugates | 1 | 2014 | 103 | 0.100 |
Why?
| | Interleukin-10 | 1 | 2015 | 300 | 0.100 |
Why?
| | Colorado | 2 | 2021 | 4406 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 1000 | 0.100 |
Why?
| | Primary Prevention | 1 | 2014 | 188 | 0.100 |
Why?
| | Myeloid Cells | 1 | 2014 | 141 | 0.100 |
Why?
| | alpha 1-Antitrypsin | 1 | 2014 | 107 | 0.100 |
Why?
| | Incidence | 1 | 2019 | 2636 | 0.100 |
Why?
| | Multiprotein Complexes | 1 | 2014 | 155 | 0.100 |
Why?
| | Celiac Disease | 1 | 2016 | 286 | 0.100 |
Why?
| | Amino Acid Motifs | 1 | 2013 | 213 | 0.100 |
Why?
| | Pancreas, Artificial | 1 | 2013 | 70 | 0.100 |
Why?
| | Aged | 5 | 2021 | 22032 | 0.100 |
Why?
| | Polymorphism, Genetic | 1 | 2015 | 639 | 0.100 |
Why?
| | Kidney Transplantation | 1 | 2018 | 671 | 0.100 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 187 | 0.100 |
Why?
| | Alum Compounds | 1 | 2011 | 22 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2018 | 824 | 0.090 |
Why?
| | Small Molecule Libraries | 1 | 2011 | 86 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 338 | 0.090 |
Why?
| | Cytokines | 2 | 2017 | 2013 | 0.090 |
Why?
| | Dendritic Cells | 1 | 2014 | 479 | 0.090 |
Why?
| | Structure-Activity Relationship | 1 | 2011 | 548 | 0.090 |
Why?
| | Whole Body Imaging | 1 | 2010 | 20 | 0.080 |
Why?
| | Dietary Proteins | 1 | 2011 | 129 | 0.080 |
Why?
| | Thyroglobulin | 1 | 2010 | 27 | 0.080 |
Why?
| | Radionuclide Imaging | 1 | 2010 | 123 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1432 | 0.080 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 54 | 0.080 |
Why?
| | Thyroidectomy | 1 | 2010 | 87 | 0.080 |
Why?
| | Iodine Radioisotopes | 1 | 2010 | 143 | 0.080 |
Why?
| | Hysterectomy | 1 | 2010 | 118 | 0.080 |
Why?
| | Self Tolerance | 1 | 2009 | 28 | 0.080 |
Why?
| | Organ Specificity | 1 | 2010 | 295 | 0.080 |
Why?
| | Immune Tolerance | 1 | 2011 | 355 | 0.080 |
Why?
| | Adrenal Insufficiency | 1 | 2009 | 32 | 0.080 |
Why?
| | Mice, Inbred BALB C | 1 | 2011 | 1247 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2014 | 1365 | 0.080 |
Why?
| | Interferon-alpha | 1 | 2010 | 194 | 0.080 |
Why?
| | Interleukin-2 | 1 | 2010 | 437 | 0.070 |
Why?
| | Sensitivity and Specificity | 3 | 2019 | 1839 | 0.070 |
Why?
| | Syndrome | 1 | 2009 | 339 | 0.070 |
Why?
| | Vaccines | 1 | 2011 | 398 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2537 | 0.060 |
Why?
| | Area Under Curve | 2 | 2016 | 304 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2017 | 5439 | 0.060 |
Why?
| | Histocompatibility Testing | 2 | 2017 | 120 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 2 | 2019 | 545 | 0.060 |
Why?
| | Risk Assessment | 1 | 2014 | 3233 | 0.060 |
Why?
| | Prospective Studies | 3 | 2023 | 7123 | 0.050 |
Why?
| | Perilipin-1 | 1 | 2023 | 16 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2022 | 1887 | 0.050 |
Why?
| | Models, Biological | 1 | 2010 | 1722 | 0.050 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2022 | 11 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2025 | 454 | 0.050 |
Why?
| | HLA-A2 Antigen | 1 | 2021 | 48 | 0.050 |
Why?
| | Transcription Factors | 1 | 2009 | 1647 | 0.040 |
Why?
| | Psychology, Child | 1 | 1981 | 36 | 0.040 |
Why?
| | Seroepidemiologic Studies | 1 | 2021 | 156 | 0.040 |
Why?
| | Neurologic Examination | 1 | 2000 | 114 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 108 | 0.040 |
Why?
| | NFATC Transcription Factors | 1 | 2020 | 84 | 0.040 |
Why?
| | HLA-B15 Antigen | 1 | 2019 | 13 | 0.040 |
Why?
| | Hand Strength | 1 | 2000 | 113 | 0.040 |
Why?
| | Genes, Reporter | 1 | 2020 | 265 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2020 | 186 | 0.040 |
Why?
| | Hand | 1 | 2000 | 155 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2014 | 1155 | 0.040 |
Why?
| | Psychotic Disorders | 1 | 1981 | 151 | 0.040 |
Why?
| | Adoptive Transfer | 1 | 2019 | 218 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2023 | 590 | 0.040 |
Why?
| | Genetic Vectors | 1 | 2020 | 312 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2021 | 332 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2018 | 184 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2018 | 76 | 0.040 |
Why?
| | Gene Editing | 1 | 2018 | 67 | 0.040 |
Why?
| | Cohort Studies | 2 | 2018 | 5409 | 0.040 |
Why?
| | Immunization | 1 | 2020 | 411 | 0.040 |
Why?
| | Molecular Dynamics Simulation | 1 | 2019 | 217 | 0.030 |
Why?
| | Gene Frequency | 1 | 2018 | 502 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2018 | 164 | 0.030 |
Why?
| | Lymphocytes | 1 | 2019 | 378 | 0.030 |
Why?
| | Receptors, CXCR3 | 1 | 2016 | 16 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2016 | 36 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 696 | 0.030 |
Why?
| | Receptors, IgG | 1 | 2016 | 73 | 0.030 |
Why?
| | Zinc Transporter 8 | 1 | 2016 | 87 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2016 | 184 | 0.030 |
Why?
| | Graft Survival | 1 | 2018 | 511 | 0.030 |
Why?
| | Cation Transport Proteins | 1 | 2016 | 131 | 0.030 |
Why?
| | Skin | 1 | 2019 | 726 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2554 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 412 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2014 | 271 | 0.030 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 52 | 0.030 |
Why?
| | Gastrins | 1 | 2013 | 9 | 0.030 |
Why?
| | Chromatography, Gel | 1 | 2014 | 126 | 0.030 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 8 | 0.030 |
Why?
| | Overweight | 1 | 2018 | 531 | 0.030 |
Why?
| | Allylamine | 1 | 2013 | 8 | 0.030 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2013 | 10 | 0.030 |
Why?
| | Bromocriptine | 1 | 2013 | 29 | 0.030 |
Why?
| | Dimerization | 1 | 2014 | 191 | 0.030 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2013 | 22 | 0.030 |
Why?
| | Drug Combinations | 1 | 2014 | 330 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2021 | 4077 | 0.030 |
Why?
| | Surface Plasmon Resonance | 1 | 2014 | 88 | 0.030 |
Why?
| | Risk Factors | 2 | 2018 | 9746 | 0.030 |
Why?
| | Risk | 1 | 2016 | 854 | 0.030 |
Why?
| | Sulfonylurea Compounds | 1 | 2013 | 46 | 0.030 |
Why?
| | Killer Cells, Natural | 1 | 2016 | 427 | 0.030 |
Why?
| | Islet Amyloid Polypeptide | 1 | 2013 | 46 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2016 | 1304 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1197 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2013 | 160 | 0.030 |
Why?
| | Toll-Like Receptors | 1 | 2014 | 179 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 420 | 0.030 |
Why?
| | Thiazolidinediones | 1 | 2013 | 137 | 0.030 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2013 | 112 | 0.020 |
Why?
| | Leptin | 1 | 2013 | 219 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2014 | 372 | 0.020 |
Why?
| | Baculoviridae | 1 | 2011 | 44 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3080 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2013 | 261 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 636 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2740 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 327 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1028 | 0.020 |
Why?
| | Thymus Gland | 1 | 2011 | 308 | 0.020 |
Why?
| | Metformin | 1 | 2013 | 315 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4057 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 3074 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2716 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2000 | 2473 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1466 | 0.020 |
Why?
| | Signal Transduction | 1 | 2020 | 4926 | 0.020 |
Why?
| | Time Factors | 1 | 2016 | 6543 | 0.020 |
Why?
| | Registries | 1 | 2013 | 1895 | 0.020 |
Why?
| | Obesity | 1 | 2018 | 2879 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5051 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7055 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2003 | 0.010 |
Why?
| | Language Development Disorders | 1 | 1981 | 46 | 0.010 |
Why?
| | Mother-Child Relations | 1 | 1981 | 135 | 0.010 |
Why?
| | Child Behavior Disorders | 1 | 1981 | 135 | 0.010 |
Why?
| | United States | 1 | 2013 | 13828 | 0.010 |
Why?
| | Family | 1 | 1981 | 644 | 0.010 |
Why?
| | Communication | 1 | 1981 | 836 | 0.010 |
Why?
|
|
Michels's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|